<?xml version="1.0" ?>
<document id="bba54a43464e4fda9280139894c5467524ef2faf">
  <chunk id="bba54a43464e4fda9280139894c5467524ef2faf.c0" text="Rational improvement of gp41- targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations"/>
  <chunk id="bba54a43464e4fda9280139894c5467524ef2faf.c1" text="Here, we report a rationally designed novel HIV-1 fusion inhibitor derived from CHR-derived peptide (Trp628~Gln653, named CP), but with an innovative Ile-Asp-Leu tail (IDL) that dramatically increased the inhibitory activity by up to 100 folds. We also determined the crystal structures of artificial fusion peptides N36-and N43-L6-CP-IDL. Although the overall structures of both fusion peptides share the canonical six-helix bundle (6-HB) configuration, their IDL tails adopt two different conformations: a one-turn helix with the N36, and a hook-like structure with the longer N43. Structural comparison showed that the hook-like IDL tail possesses a larger interaction interface with NHR than the helical one. Further molecular dynamics simulations of the two 6-HBs and isolated CP-IDL peptides suggested that hook-like form of IDL tail can be stabilized by its binding to NHR trimer. Therefore, CP-IDL has potential for further development as a new HIV fusion inhibitor, and this strategy could be widely used in developing artificial fusion inhibitors against HIV and other enveloped viruses.">
    <entity charOffset="57-66" id="bba54a43464e4fda9280139894c5467524ef2faf.c1.e0" ontology_id="CHEBI_35222" text="inhibitor" type="chemical"/>
    <entity charOffset="92-99" id="bba54a43464e4fda9280139894c5467524ef2faf.c1.e1" ontology_id="CHEBI_16670" text="peptide" type="chemical"/>
    <entity charOffset="168-171" id="bba54a43464e4fda9280139894c5467524ef2faf.c1.e2" ontology_id="CHEBI_132933" text="IDL" type="chemical"/>
    <entity charOffset="308-316" id="bba54a43464e4fda9280139894c5467524ef2faf.c1.e3" ontology_id="CHEBI_16670" text="peptides" type="chemical"/>
    <entity charOffset="387-395" id="bba54a43464e4fda9280139894c5467524ef2faf.c1.e4" ontology_id="CHEBI_16670" text="peptides" type="chemical"/>
    <entity charOffset="461-464" id="bba54a43464e4fda9280139894c5467524ef2faf.c1.e5" ontology_id="CHEBI_132933" text="IDL" type="chemical"/>
    <entity charOffset="632-635" id="bba54a43464e4fda9280139894c5467524ef2faf.c1.e6" ontology_id="CHEBI_132933" text="IDL" type="chemical"/>
    <entity charOffset="789-797" id="bba54a43464e4fda9280139894c5467524ef2faf.c1.e7" ontology_id="CHEBI_16670" text="peptides" type="chemical"/>
    <entity charOffset="831-834" id="bba54a43464e4fda9280139894c5467524ef2faf.c1.e8" ontology_id="CHEBI_132933" text="IDL" type="chemical"/>
    <entity charOffset="953-973" id="bba54a43464e4fda9280139894c5467524ef2faf.c1.e9" ontology_id="CHEBI_59886" text="HIV fusion inhibitor" type="chemical"/>
    <entity charOffset="964-973" id="bba54a43464e4fda9280139894c5467524ef2faf.c1.e10" ontology_id="CHEBI_35222" text="inhibitor" type="chemical"/>
    <entity charOffset="1046-1056" id="bba54a43464e4fda9280139894c5467524ef2faf.c1.e11" ontology_id="CHEBI_35222" text="inhibitors" type="chemical"/>
  </chunk>
</document>
